Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:52:39.779Z.
Calculation as of: 2026-10-06T18:52:39.779Z.
Quote observation: 2026-10-06T18:50:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 23d17170dcd90d56222e16e6e1c46ca5d6e49f0f5e08d353dc7d5f06f7b1586d
PE RATIO
N/A
Market Cap
$8.89B
PE Ratio
133.78
TTM Avg
133.81
3Y Avg
61.10
5Y Avg
61.10
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | $9.42B | N/A | N/A | N/A | N/A |
| Insulet Corp. (PODD)vs › | $9.37B | 25.28 | 58.80 | 65.23 | 3594.22 |
| Krystal Biotech, Inc. (KRYS)vs › | $9.62B | 40.89 | 40.13 | 207.84 | 207.84 |
| Henry Schein, Inc. (HSIC)vs › | $9.64B | 24.68 | 23.93 | 23.91 | 21.89 |
| Bruker Corporation (BRKR)vs › | $9.18B | N/A | 54.08 | 39.03 | 41.91 |
| Axsome Therapeutics, Inc. (AXSM)vs › | $9.04B | N/A | N/A | N/A | N/A |
| Bruker Corporation (BRKRP)vs › | $8.91B | N/A | 552.62 | 552.62 | 552.62 |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.89B | 133.78 | 133.81 | 61.10 | 61.10 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.95B | 44.81 | 33.97 | 32.01 | 20.98 |
| Repligen Corporation (RGEN)vs › | $10.04B | 243.62 | 2667.34 | 1448.16 | 807.09 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$65.22
Forward EPS (Est.)
$-8.27
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
